Technology Review - Published By MIT
Advertisement
TO READ THIS STORY - you must have a paid subscription to Technology Review OR you can purchase special archive reading credits here. Choose from these great offers below.
I'm a paid subscriber please
log me in
I want to purchase this article for
only 99¢
(requires login)
I want to purchase five articles for
only $3.99
(requires login)
I want to buy
1 Year TOTAL Access for
only $24.95
(requires login)

Please note: Click here if you are currently a Technology Review print or digital subscriber and do not have access to this article.

Click here if you are an MIT alum and do not have access to this article.

November 2004

Modular Drugs

By Karen Epper Hoffman

Over the past decade, biotech companies have introduced a string of protein-based antibody drugs, which mimic the action of the body's own immune system to combat conditions like cancer and arthritis. Antibody drugs can zero in precisely on misbehaving cells and often enlist the aid of our own antibodies to force a disease into retreat. But there's a price for their effectiveness. Antibody drugs are based on large molecules, so they have a hard time getting into the bloodstream and into cells.

Select from the choices above
to read the entire article.


Log In

Forgot your password?     Register »
Advertisement

Videos

The Marcellus Shale Gas Rush
Technology Review November/December 2009

Current Issue

Natural Gas Changes the Energy Map
The United States has vast supplies of this cleaner fossil fuel. But how should we use it?
Advertisement
Advertisement
Subscribe to Technology Review's daily e-mail update. Enter your e-mail address

TECHNOLOGY RESOURCES

More Technology News from Forbes

Advertisement
MIT Massachusetts Institute of Technology © 2009 Technology Review. All Rights Reserved.